ICYMI: A new pneumococcal vaccine just outperformed Pfizer and Merck in trials #PneumococcalVaccine #Vaxcyte

ICYMI: A new pneumococcal vaccine just outperformed Pfizer and Merck in trials #PneumococcalVaccine #Vaxcyte
Shares in #Vaxcyte have rocketed on the revelation of phase 3 trial data for its #pneumococcalvaccine (PCV) candidate VAX-31, which suggests it could be a threat to already-marketed shots from Pfizer and MSD.